References
- Mattick RP, Breen C, Kimber J, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2):CD002207.
- Teruya C, Schwartz RP, Mitchell SG, et al. Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the Starting Treatment with Agonist Replacement Therapies (START) study. J Psychoactive Drugs. 2014;46(5):412–426.
- Ahmed S, Bhivandkar S, Lonergan BB, et al. Microinduction of buprenorphine/naloxone: a review of the literature. Am J Addict. 2021;30(4):305–315.
- De Aquino JP, Parida S, Sofuoglu M. The pharmacology of buprenorphine microinduction for opioid use disorder. Clin Drug Investig. 2021;41(5):425–436.
- Hämmig R, Kemter A, Strasser J, et al. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the bernese method. Subst Abuse Rehabil. 2016;7:99–105.
- Tang VM, Lam-Shang-Leen J, Brothers TD, et al. Case series: limited opioid withdrawal with use of transdermal buprenorphine to bridge to sublingual buprenorphine in hospitalized patients. Am J Addict. 2020;29(1):73–76.
- Raheemullah A, Lembke A. Buprenorphine induction without opioid withdrawal: a case series of 15 opioid-dependent inpatients induced on buprenorphine using microdoses of transdermal buprenorphine. Am J Ther. 2019;28(4):e504–e508.
- Raheemullah A, Lembke A. Initiating opioid agonist treatment for opioid use disorder in the inpatient setting: a teachable moment. JAMA Intern Med. 2019;179(3):427–428.
- Saal D, Lee F. Rapid induction therapy for opioid-use disorder using buprenorphine transdermal patch: a case series. Perm J. 2020;24:19.124.
- Kinasz KR, Herbst ED, Kalapatapu RK. Case report: buprenorphine induction using transdermal buprenorphine in a veteran with opioid use disorder and psychosis, managing precipitated withdrawal. Mil Med. 2020;185(9–10):e1872–e1875.
- Galati BM, Carter EB, Perez M, et al. Buprenorphine patch as a bridge to sublingual treatment of opioid use disorder in pregnancy. Obstet Gynecol. 2021;137(4):713–716.
- Cortina S, Mihic T, Fennemore M, et al. Case report: high-dose methadone transition to buprenorphine/naloxone in an inpatient with a prolonged QT interval. Can J Addict. 2017;8:25–28.
- De Aquino JP, Fairgrieve C, Klaire S, et al. Rapid transition from methadone to buprenorphine utilizing a micro-dosing protocol in the outpatient veteran affairs setting. J Addict Med. 2020;14(5):e271–e273.
- Kornfeld H, Reetz H. Transdermal buprenorphine, opioid rotation to sublingual buprenorphine, and the avoidance of precipitated withdrawal: a review of the literature and demonstration in three chronic pain patients treated with butrans. Am J Ther. 2015;22(3):199–205.
- Hess M, Boesch L, Leisinger R, et al. Transdermal buprenorphine to switch patients from higher dose methadone to buprenorphine without severe withdrawal symptoms. Am J Addict. 2011;20(5):480–481.
- von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet Lond Engl. 2007;370(9596):1453–1457.
- Von Korff M, Saunders K, Ray GT, et al. Defacto long-term opioid therapy for non-cancer pain. Clin J Pain. 2008;24(6):521–527.